CoChat

Cotinine, a Neuroactive Metabolite of Nicotine: Potential for Treating Disorders of Impaired Cognition

Open access
Terry, Alvin V., Hernandez, Caterina M., Hohnadel, Elizabeth J., Bouchard, Kristy P., Buccafusco, Jerry J. · 2005 · CNS Drug Reviews
Cited by 76

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

The pharmacological effects of the tobacco‐derived alkaloid nicotine have been widely studied in humans and animals for decades. However, relatively little attention has been given to the potential actions of its major metabolite, cotinine. After nicotine consumption the duration of cotinine's presence in blood and brain greatly exceeds that of nicotine. Therefore, cotinine could mediate the more protracted pharmacological effects of nicotine. The studies described in this report were thus designed to further investigate certain neuropharmacological actions of cotinine. Behavioral tests (e.g., delayed matching‐to‐sample) were conducted in aged rhesus monkeys to assess the effects of cotinine on working memory and attention. In rats a prepulse inhibition (PPI) procedure was used to assess the effects of the compound on auditory gating — a method for predicting the potential antipsychotic properties of drugs. Cotinine exhibited significant effectiveness in these tasks. The drug was also cytoprotective in differentiated PC‐12 cells with a potency equivalent to that of nicotine. The effects of chronic cotinine treatment on the expression of nicotinic and muscarinic acetylcholine receptors in rat brain were measured by [125 I]epibatidine, [125 I]α‐bungarotoxin ([125 I]BTX), [3 H]pirenzepine ([3 H]PRZ), and [3 H]AFDX‐384 ([3 H]AFX) autoradiography. Unlike nicotine, cotinine failed to upregulate the expression of brain nicotinic receptors. Based on its relative safety in man, cotinine should prove useful in the treatment of diseases of impaired cognition and behavior without exhibiting the toxicity usually attributed to nicotine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1527-3458.2005.tb00045.x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 76

Metadata

Authors
Terry, A. V., Hernandez, C. M., Hohnadel, E. J., Bouchard, K. P., & Buccafusco, J. J.
Venue
CNS Drug Reviews
Publisher
Wiley
Published
2005-09
Volume
11
Issue
3
Pages
229-252
ISSN
  • 1080-563X (ISSN-L)
  • 1527-3458
OpenAlex
W2117585066
Cited by
76
References
3
FWCI
1.15
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cotinine, a Neuroactive Metabolite of Nicotine: Potential for Treating Disorders of Impaired Cognition. https://app.cochat.ai/papers/10.1111/j.1527-3458.2005.tb00045.x
The paper
Terry, A. V., Hernandez, C. M., Hohnadel, E. J., Bouchard, K. P., & Buccafusco, J. J. (2005). Cotinine, a Neuroactive Metabolite of Nicotine: Potential for Treating Disorders of Impaired Cognition. CNS Drug Reviews. https://doi.org/10.1111/j.1527-3458.2005.tb00045.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.